Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 12 - Non-invasive prenatal diagnosis for fetal blood group status

  • Edited by Sean Kehoe, Lyn Chitty, Tessa Homfray
  • Book:
    Reproductive Genetics
    Published online:
    05 February 2014
    Print publication:
    01 November 2009, pp 173-182

  • Summary

    A problem in all tests on fetal DNA derived from maternal plasma arises from the large quantity of maternal DNA present in the DNA preparation, complicating the inclusion of satisfactory internal controls to test for successful amplification of the fetal DNA. As increasing number of laboratories internationally are introducing non-invasive fetal blood group testing, it is important that their performances are monitored through external quality assurance schemes. Fetal RHD screening provides a way of significantly reducing the quantity of blood products given routinely to pregnant women. To date, the enormous promise of the application of free fetal DNA in maternal plasma to prenatal diagnostics has only been realised in fetal blood grouping and fetal sexing. Fetal blood grouping often plays an important role in avoidance of unnecessary procedures and is the standard of care in England for pregnant women with significant level of anti-D immunoglobulin.